Breaking News Instant updates and real-time market news.

ACET

Aceto

$7.40

(0.00%)

, NVS

Novartis

$81.72

(0.00%)

09:37
04/19/18
04/19
09:37
04/19/18
09:37

Wells says bottom has not been reached in generics pricing

After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).

ACET

Aceto

$7.40

(0.00%)

NVS

Novartis

$81.72

(0.00%)

TEVA

Teva

$17.91

(0.00%)

MYL

Mylan

$40.73

(0.00%)

  • 23

    Apr

  • 27

    Apr

  • 17

    May

  • 18

    May

  • 21

    May

  • 05

    Jun

  • 16

    Jun

  • 13

    Nov

ACET Aceto
$7.40

(0.00%)

04/19/18
ADAM
04/19/18
DOWNGRADE
ADAM
Sell
Aceto downgraded to Sell from Buy at Canaccord
07/31/17
ADAM
07/31/17
INITIATION
Target $19
ADAM
Buy
Aceto initiated with a Buy at Canaccord
Canaccord Genuity analyst Dewey Steadman started Aceto with a Buy rating and $19 price target. The analyst likes the company's "unique" asset-light business model strategy.
08/28/17
ADAM
08/28/17
NO CHANGE
Target $15
ADAM
Buy
Aceto price target lowered to $15 from $19 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target on Aceto to $15 from $19 following Q3 earnings. The analyst said its bottom-line performance was disappointing due to a meaningful step-down in gross margins due to low-margin launches and continued contributions from its Citron acquisition. Steadman maintained his Buy rating on Aceto shares as he is still positive on its potential for growth driven by new product launches and product approvals.
04/19/18
ADAM
04/19/18
DOWNGRADE
Target $2
ADAM
Sell
Aceto double downgraded to Sell at Canaccord
As reported previously, Canaccord analyst Dewey Steadman downgraded Aceto two notches, to Sell from Buy, citing a rapid degradation of the company's asset-light business model in the wake of continued pressures for commoditized generics. The company's core human health business has been under significant pressure and has been unable to swiftly adapt to market conditions, said Steadman, who lowered his price target to $2 from $10 on Aceto shares after the company last night said it was suspending further guidance and reducing its dividend.
NVS Novartis
$81.72

(0.00%)

04/18/18
JEFF
04/18/18
DOWNGRADE
Target $218
JEFF
Hold
AveXis downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded AveXis (AVXS) to Hold while raising his price target for the shares to $218 from $141. The analyst's downgrade and new price target reflect the pending acquisition by Novartis (NVS).
04/16/18
ROTH
04/16/18
NO CHANGE
Target $27
ROTH
Buy
CymaBay seladelpar a 'clear winner' from EASL, says Roth Capital
Roth Capital analyst Yasmeen Rahimi notes that Novartis (NVS) reported disappointing 28-day interim results from its FXR agonist in 49 PBC patients at EASL. Tropifexor had AP level drops far below CymaBay's (CBAY) seldelpar at 4 weeks, she points out, adding that she believes seladelpar is a "clear winner" from Paris. Rahimi reiterates a Buy rating and $27 price target on CymaBay's shares.
04/12/18
LEHM
04/12/18
DOWNGRADE
Target $218
LEHM
Equal Weight
AveXis downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded AveXis (AVXS) to Equal Weight to reflect the proposed takeover by Novartis (NVS). The analyst sees limited antitrust risks and a low probability of a counterbid. She raised her price target for AveXis shares to $218 from $152. She believes the price being paid by Novartis fully reflects the value of the stock.
04/18/18
BERN
04/18/18
NO CHANGE
BERN
Spark Therapeutics, uniQure may be potential takeout targets, says Bernstein
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
TEVA Teva
$17.91

(0.00%)

02/13/18
WELS
02/13/18
NO CHANGE
WELS
Teva generic comes earlier than expected, says Wells Fargo
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
02/21/18
DBAB
02/21/18
NO CHANGE
Target $20
DBAB
Hold
Deutsche sees rifamycin as possible long-term threat to Valeant
The outlook for Valeant Pharmaceuticals' (VRX) Xifaxan, which represents 13% of the company's revenue, improved last year following safety issues for competitor Viberzi and delays for generic challenger Teva (TEVA), Deutsche Bank analyst Gregg Gilbert tells investors in a research note. More recently, the analyst notes, questions have been raised as to whether Cosmo's rifamycin could pose a threat to Xifaxan, either in the near term from off-label prescribing for irritable bowel syndrome with diarrhea, or longer term if eventually approved for IBS-D. After due diligence, Gilbert believes rifamycin could potentially be a longer-term threat to Xifaxan if it works for IBS-D, but he does not see "material risk" from off-label use in the interim. His model continues to assume mid-single digit Xifaxan sales growth for several years and a generic cliff in 2025. The analyst keeps a Hold rating on Valeant with a $20 price target.
03/20/18
JEFF
03/20/18
INITIATION
Target $19
JEFF
Hold
Teva resumed with a Hold at Jefferies
Jefferies analyst David Steinberg resumed coverage of Teva Pharmaceutical with a Hold rating and $19 price target. The analyst sees "headwinds on multiple fronts" and believes the positive outlook for Austedo and fremanezumab is priced in with the shares trading at 10 times 2020 consensus EBITDA.
03/26/18
RBCM
03/26/18
NO CHANGE
Target $16
RBCM
Sector Perform
RBC Capital concerned with 'overly ambitious' consensus assumptions for Teva
RBC Capital analyst Randall Stanicky lowered his price target on Teva to $16 from $18, saying that his own model contrasts with "overly optimistic" consensus regarding the P&L assumptions in the company's Branded segment. Specifically, the analyst is concerned with the rising generic competition for Teva's Copaxone as well as fremanezumab, which he expects to miss the June 16 PDUFA "given Celltrion's outstanding Warning Letter" while lowering his peak sales projections by $200M to $1B. Stanicky keeps his Sector Perform rating on Teva, adding that the multi-year turnaround investment thesis on the stock is not supported at this point.
MYL Mylan
$40.73

(0.00%)

04/12/18
JPMS
04/12/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan shares remain 'highly inexpensive,' says JPMorgan
JPMorgan analyst Chris Schott says his positive longer term thesis is unchanged following Mylan's investor day. Commentary on the near-term pipeline remained upbeat and Mylan highlighted multiple long-term revenue drivers, Schott tells investors in a research note. He believes the company's "significant" generic Advair opportunity, as well as other potential near-term approvals, more than offset any downside risk from ongoing challenges in the U.S. generics market. The analyst thinks Mylan shares remain "highly inexpensive." Schott keeps an Overweight rating on the name with a $53 price target.
04/12/18
04/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Incyte (INCY) upgraded to Buy from Neutral at UBS with analyst Carter Gould saying the stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models. 2. TechnipFMC (FTI) upgraded to Buy from Neutral at Goldman Sachs with analyst Waqar Syed saying while his 2018/2019 EBITDA estimates are little changed, his 2020 EBITDA estimates have been raised nearly 18% owing to expectations for higher inbound orders in 2019 for the Subsea and Onshore/Offshore segments. 3. Prologis (PLD) upgraded to Buy from Hold at Jefferies with analyst Jonathan Petersen saying he sees the company posting one of the strongest levels of internal growth among the blue-chip real estate investment trusts in 2018. 4. Mylan (MYL) upgraded to Outperform from Market Perform at Leerink with analyst Ami Fadia citing valuation disconnect given the diversified business and catalyst path. 5. Summit Hotel Properties (INN) upgraded to Buy from Underperform at BofA/Merrill with analyst Shaun Kelley citing relative valuation, its potential to outperform peers on the top-line in an accelerating RevPAR environment, and lower relative cost pressure given a lower proportion of labor costs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
04/12/18
UPGRADE
Target $52

Outperform
Mylan upgraded to Outperform at Leerink
As previously reported, Leerink analyst Ami Fadia upgraded Mylan to Outperform from Market Perform, with a $52 price target, citing valuation disconnect given the diversified business and catalyst path.
04/18/18
LEHM
04/18/18
NO CHANGE
Target $230
LEHM
Overweight
Barclays sees 'significant challenges' for Botox biosimilar
Barclays analyst Douglas Tsao says that while he'd probably stop short of calling it "mission impossible," he sees "significant challenges" in the development of a biosimilar to Allergan's (AGN) Botox. Following a deep dive into the key issues Mylan (MYL) will likely face in developing a biosimilar Botox, the analyst and concluded that it seems "technically difficult and faces a long road ahead." Even a best case scenario puts timing out to 2023, Tsao tells investors in a research note. The analyst has an Overweight rating on Allergan with a $230 price target.

TODAY'S FREE FLY STORIES

23:35
09/18/18
09/18
23:35
09/18/18
23:35
General news
Bank of Japan maintained the -0.1% policy rate »

Bank of Japan maintained…

INGIY

Ingenico

$0.00

(0.00%)

20:59
09/18/18
09/18
20:59
09/18/18
20:59
Upgrade
Ingenico rating change at Goldman Sachs »

Ingenico upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

MSFT

Microsoft

$113.24

1.05 (0.94%)

20:52
09/18/18
09/18
20:52
09/18/18
20:52
Hot Stocks
Microsoft announces new AI and mixed reality business applications for Dynamics »

In its official blog,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

BWA

BorgWarner

$42.99

-1.17 (-2.65%)

19:34
09/18/18
09/18
19:34
09/18/18
19:34
Hot Stocks
BorgWarner sees operating margins in low-13% by FY23 vs 12.4% in FY17 »

As part of its Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 25

    Oct

JLL

Jones Lang LaSalle

$144.15

0.795 (0.55%)

19:31
09/18/18
09/18
19:31
09/18/18
19:31
Hot Stocks
Jones Lang LaSalle CFO Christie Kelly resigns »

Jones Lang LaSalle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

RACE

Ferrari

$138.31

5.465 (4.11%)

19:24
09/18/18
09/18
19:24
09/18/18
19:24
Earnings
Ferrari sees FY18 revenue over EUR3.4B »

As part of its Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

, INAP

Internap

$12.39

-0.33 (-2.59%)

19:02
09/18/18
09/18
19:02
09/18/18
19:02
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Stein Mart (SMRT)…

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

INAP

Internap

$12.39

-0.33 (-2.59%)

TRVG

Trivago

$5.13

0.26 (5.34%)

PRQR

ProQR Therapeutics

$20.25

-1.4 (-6.47%)

MSFT

Microsoft

$113.24

1.05 (0.94%)

EVOP

EVO Payments

$26.27

-0.42 (-1.57%)

TSM

TSMC

$43.57

-0.2 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 12

    Nov

  • 15

    Nov

  • 03

    Mar

  • 21

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

18:58
09/18/18
09/18
18:58
09/18/18
18:58
Periodicals
China to place new tariffs on $60B in U.S. exports, WSJ says »

China's government…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$87.97

1.1 (1.27%)

18:55
09/18/18
09/18
18:55
09/18/18
18:55
Periodicals
Square seeks to bring 'omnichannel' experience to restaurants, CNBC says »

Square CFO Sarah Friar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 26

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:48
09/18/18
09/18
18:48
09/18/18
18:48
Hot Stocks
Microsoft confirms raised quarterly dividend payment to 46c from 42c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

KL

Kirkland Lake Gold

$17.57

-0.64 (-3.51%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Kirkland Lake Gold acquires shares of Osisko Mining »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

OMAB

OMA Airports

$56.18

2.13 (3.94%)

18:23
09/18/18
09/18
18:23
09/18/18
18:23
Downgrade
OMA Airports rating change at Santander »

OMA Airports downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$113.41

-0.03 (-0.03%)

18:01
09/18/18
09/18
18:01
09/18/18
18:01
Hot Stocks
Celanese raises prices for acetate tow in Eastern Europ and Asia by $1/kg »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$132.97

0.56 (0.42%)

17:58
09/18/18
09/18
17:58
09/18/18
17:58
Periodicals
Wynn sued over allegations of rigging Boston casino bid, Bloomberg says »

Wynn Resorts and former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$113.43

-0.18 (-0.16%)

17:48
09/18/18
09/18
17:48
09/18/18
17:48
Hot Stocks
SPDR Gold Trust holdings fall to 742.23MT from 742.53MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$161.89

0.92 (0.57%)

17:35
09/18/18
09/18
17:35
09/18/18
17:35
Recommendations
Jazz Pharmaceuticals analyst commentary at BMO Capital »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 27

    Oct

  • 27

    Nov

  • 20

    Dec

RIG

Transocean

$11.93

0.335 (2.89%)

17:29
09/18/18
09/18
17:29
09/18/18
17:29
Initiation
Transocean initiated at Morgan Stanley »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NE

Noble Corp.

$6.15

0.19 (3.19%)

17:26
09/18/18
09/18
17:26
09/18/18
17:26
Initiation
Noble Corp. initiated at Morgan Stanley »

Noble Corp. initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CCOEY

Capcom

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Periodicals
Capcom shutting down Vancouver studio, Kotaku says »

Capcom Vancouver,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$77.70

0.67 (0.87%)

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Syndicate
Breaking Syndicate news story on Best Buy »

Best Buy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DO

Diamond Offshore

$17.86

0.55 (3.18%)

17:22
09/18/18
09/18
17:22
09/18/18
17:22
Initiation
Diamond Offshore initiated at Morgan Stanley »

Diamond Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$43.57

-0.2 (-0.46%)

17:20
09/18/18
09/18
17:20
09/18/18
17:20
Upgrade
TSMC rating change at Morgan Stanley »

TSMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHD

Cactus

$35.93

1.24 (3.57%)

17:17
09/18/18
09/18
17:17
09/18/18
17:17
Initiation
Cactus initiated at Morgan Stanley »

Cactus initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:15
09/18/18
09/18
17:15
09/18/18
17:15
Periodicals
Senators seek punishment if ZTE strays from deal, Reuters says »

In a bill, introduced on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.